Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Carcinoma, Non-Small-Cell Lung 24Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 11Lung Neoplasms 11Neoplasm Metastasis 10Carcinoma, Hepatocellular 9Breast Neoplasms 9Pancreatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Triple Negative Breast Neoplasms 7Advanced Solid Tumors 7Melanoma 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Recurrence 3Multiple Myeloma 3Head and Neck Neoplasms 3Diabetes Mellitus, Insulin-Dependent, 12 3Advanced Solid Tumours 3Vulvar Neoplasms 2Vaginal Neoplasms 2Solid Tumor 2

Interventions

Cyclophosphamide 61Rituximab 60Etoposide 28fludarabine phosphate 23Prednisone 23fludarabine 22Vincristine 19Filgrastim 19Doxorubicin 19ibrutinib 16Peripheral Blood Stem Cell Transplantation 16venetoclax 15Lenalidomide 14Bortezomib 14Carboplatin 13CT-P10 13Gemcitabine 12Vorinostat 11Cytarabine 11pembrolizumab 9Radiotherapy 9Melphalan 9Magnetic Resonance Spectroscopy 9Dexamethasone 9Bendamustine Hydrochloride 9Paclitaxel 8Ifosfamide 8Cyclosporine 8Biopsy 8Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large B-Cell, Diffuse × durvalumab × Clear all
NCT03610061 2024-04-12

RaDD

Austin Health

Phase 1 Completed
34 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02706405 2022-08-24

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
30 enrolled 29 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03685344 2021-10-26

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

ADC Therapeutics S.A.

Phase 1 Terminated
13 enrolled 15 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

MedImmune LLC

Phase 1 Completed
32 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡